T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patients by Viborg, Nadia et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
T cell recognition of novel shared breast cancer antigens is frequently observed in
peripheral blood of breast cancer patients
Viborg, Nadia; Ramskov, Sofie; Andersen, Rikke Sick; Sturm, Theo; Fugmann, Tim; Bentzen,
Amalie Kai; Rafa, Vibeke Mindahl; Straten, Per thor; Svane, Inge Marie; Met, Özcan; Hadrup,
Sine Reker
Published in:
OncoImmunology
DOI:
10.1080/2162402X.2019.1663107
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Viborg, N., Ramskov, S., Andersen, R. S., Sturm, T., Fugmann, T., Bentzen, A. K., ... Hadrup, S. R. (2019). T
cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast
cancer patients. OncoImmunology, 8(12), [1663107]. https://doi.org/10.1080/2162402X.2019.1663107
Download date: 03. Feb. 2020
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=koni20
OncoImmunology
ISSN: (Print) 2162-402X (Online) Journal homepage: https://www.tandfonline.com/loi/koni20
T cell recognition of novel shared breast cancer
antigens is frequently observed in peripheral
blood of breast cancer patients
Nadia Viborg, Sofie Ramskov, Rikke Sick Andersen, Theo Sturm, Tim
Fugmann, Amalie Kai Bentzen, Vibeke Mindahl Rafa, Per thor Straten, Inge
Marie Svane, Özcan Met & Sine Reker Hadrup
To cite this article: Nadia Viborg, Sofie Ramskov, Rikke Sick Andersen, Theo Sturm, Tim
Fugmann, Amalie Kai Bentzen, Vibeke Mindahl Rafa, Per thor Straten, Inge Marie Svane, Özcan
Met & Sine Reker Hadrup (2019) T cell recognition of novel shared breast cancer antigens
is frequently observed in peripheral blood of breast cancer patients, OncoImmunology, 8:12,
e1663107, DOI: 10.1080/2162402X.2019.1663107
To link to this article:  https://doi.org/10.1080/2162402X.2019.1663107
© 2019 The Author(s). Published with
license by Taylor & Francis Group, LLC.
View supplementary material 
Published online: 30 Sep 2019. Submit your article to this journal 
Article views: 559 View related articles 
View Crossmark data
ORIGINAL RESEARCH
T cell recognition of novel shared breast cancer antigens is frequently observed in
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Amalie Kai Bentzen a, Vibeke Mindahl Rafaa, Per thor Straten b,d, Inge Marie Svane b, Özcan Met b,d,
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aDepartment of Health Technology, Technical University of Denmark, Lyngby, Denmark; bCenter for Cancer Immune Therapy, Copenhagen
University Hospital, Herlev, Denmark; cPhilochem AG, Otelfingen, Switzerland; dDepartment of Immunology and Microbiology, Faculty of Health
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ABSTRACT
Advances within cancer immunotherapy have fueled a paradigm shift in cancer treatment, resulting in
increasing numbers of cancer types benefitting from novel treatment options. Despite originally being
considered an immunologically silent malignancy, recent studies encourage the research of breast
cancer immunogenicity to evaluate immunotherapy as a treatment strategy. However, the epitope
landscape in breast cancer is minimally described, limiting the options for antigen-specific, targeted
strategies. Aromatase, never in mitosis A-related kinase 3 (NEK3), protein inhibitor of activated STAT3
(PIAS3), and prolactin are known as upregulated proteins in breast cancer. In the present study, these
four proteins are identified as novel T cell targets in breast cancer.
From the four proteins, 147 peptides were determined to bind HLA-A*0201 and -B*0702 using
a combined in silico/in vitro affinity screening. T cell recognition of all 147 peptide-HLA-A*0201/-B*0702
combinations was assessed through the use of a novel high-throughput method utilizing DNA barcode
labeled multimers.
T cell recognition of sequences within all four proteins was demonstrated in peripheral blood of
patients, and significantly more T cell responses were detected in patients compared to healthy donors
for both HLA-A*0201 and -B*0702. Notably, several of the identified responses were directed toward
peptides, with a predicted low or intermediate binding affinity. This demonstrates the importance of
including low-affinity binders in the search for epitopes within shared tumor associated antigens (TAAs),
as these might be less subject to immune tolerance mechanisms.
The study presents four novel TAAs containing multiple possible targets for immunotherapy of breast
cancer.
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Introduction
Throughout the last decade, the remarkable progress in the
field of cancer immunotherapy has resulted in a paradigm
shift in cancer treatment, establishing immunotherapy as the
fourth pillar of treatment, next to conventional therapies; sur-
gery, radiation, and chemotherapy. Unprecedented improve-
ments of response rate and overall survival have been shown
for an increasing range of cancer types, with various forms of
immunotherapy.
Breast cancer remains the largest group of female cancers
and a major cause of death, despite improvements in time of
diagnosis and range of treatment options.1,2 Although gener-
ally considered to be poorly immunogenic, an increasing body
of evidence points to a role of immunotherapy in breast
cancer, especially in triple negative breast cancer, the subtype
where other treatment options are extremely limited.3 In
recent years, a major focus of immune therapy has been on
mutation-derived neo-antigens, with mutational burden and
predicted number of neo-antigens shown to correlate with
favorable clinical outcome and benefit from immune check-
point therapy.4–6
However, the burden of somatic mutations varies greatly
between tumor types,7 as do the chances of identifying patient-
specific targetable neo-antigens, to which effector cells of the
immune system can be actively directed. Breast cancers are
among low mutational burden tumors and although a recent
study demonstrated the presence of neo-antigen reactive T cells
in tumor infiltrating lymphocytes (TILs) used to treat a breast
cancer patient who obtained a complete durable regression,8 we
would argue that the group of shared tumor associated antigens
(TAAs) may play an additional role in this cancer type. TAAs are
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of value both in the antigen-defined treatment setting, where
they can act directly as targets of therapy, as well as in the
antigen-undefined setting, where they can be used for immuno-
monitoring and potentially be able to predict treatment
outcome.9 Few breast cancer-specific TAAs are known; those
that have already been described (e.g. HER210 and MUC111) are
only expressed in subgroups of patients; and when used in
vaccines, they have shown limited clinical activity, albeit modest
immunological activity.2 Therefore, there is an unmet need for
identification of TAAs in breast cancer.
In this study we investigate aromatase, prolactin, never in
mitosis A-related kinase 3 (NEK3) and protein inhibitor of
activated signal transducer and activator of transcription 3
(PIAS3) as possible TAAs in breast cancer. Aromatase is the
key enzyme in estrogen synthesis and is a heterodimer composed
of the ubiquitously expressed flavoprotein NADPH-cytochrome
P450 reductase and aromatase cytochrome P450.12 Aromatase
inhibitors are already successful in treating breast and other
female cancers, underlining the relevance of investigating aro-
matase as a TAA.13 Prolactin and two of its downstream intra-
cellular signaling proteins, NEK3 and PIAS3, are involved in
breast lobulo-alveolar expansion and differentiation prior to
milk synthesis and secretion.14,15 All four proteins have been
described to have an increased expression in breast cancer com-
pared to healthy breast tissue.12–16
Results
Peptides were selected based on a combined in silico and
in vitro selection pipeline
The four proteins aromatase, NEK3, PIAS3, and prolactin were
selected for investigation based on a literature search, prioritiz-
ing proteins that fulfilled criteria of tissue restriction and
increased expression in malignant compared to healthy breast
tissue (Table 1). Aromatase mRNA levels have been shown to be
significantly increased in breast cancer compared to healthy
breast tissue, e.g. in a study by Harada, where mRNA levels
were significantly elevated (p < 0.01).16 Likewise, significantly
increased expression of prolactin, and the two intracellular sig-
naling proteins, NEK3 and PIAS3, have been demonstrated
in breast tumor tissue using immunohistochemistry staining.
This revealed a significant difference in expression between
normal/hyperplastic epithelium and ductal carcinoma in situ/
invasive carcinoma (t-tests, all p values < 0.02).14
Expression of all four proteins was validated in two breast
ductal carcinoma cell lines (BT-549 and HCC1937), as well as
in two breast adenocarcinoma cell lines (EFM-192A and
MDA-MB-231) (Supplementary Figure S1). MHC class
I presentation of peptides from the four proteins was investi-
gated by mass spectrometry analysis and demonstrated pre-
sentation of peptides from PIAS3 in three of three tested cell
lines (Supplementary Figure S1, Supplementary Table S3).
A library of peptides was generated based on a two-step in
silico + in vitro selection process (Table 2, Supplementary Table
S2). In the initial in silico prediction step, two available computa-
tional pipelines, SYFPEITHI and NetMHC 3.0, were used for
predicting the MHC class I binding affinity of the individual
peptides in the selected proteins. We identified potential HLA-
A*0201 and -B*0702 binding 9- and 10-mer peptides within the
sequences of the four proteins. The number of predicted peptides
out of total possible peptides from each protein sequence corre-
lated with the size of the protein, as would be expected. 415 of the
total 3644 peptides were predicted with selection cut offs set to
accommodate inclusion of both high and low affinity HLA-
A*0201 and -B*0702 ligands (SYFPEITHI: ≥ 19, NetMHC 3.0:
≤ 1000 nM), given that the proteins of interest are shared anti-
gens. Previous analyses have demonstrated very low affinity
epitopes of relevance in shared antigens.17, 18 As such, the binding
of the predicted peptides was experimentally tested in vitro with
anMHC ELISA.19 147 of the 415 in silico predicted peptides were
selected for further analysis, based on 50% (A*0201) and 70%
(B*0702) binding affinity, compared to a reference of high affinity
virus-derived ligands (Table 2, Supplementary Table S2).
Table 1. Overview of protein targets selected for investigation as tumor associated antigens.
Protein Full name Normal function Role in breast cancer Normal expression
Increased
expression Reference
Aromatase Aromatase Key enzyme in estrogen synthesis.
Heterodimer composed of aromatase
cytochrome P450 and NADPH-cytochrome
P450 reductasea
Enhanced tumor cell
growth
Breast, ovary, testes,
adipose tissue, skin,
hypothalamus,
placenta
Breast,
endometrial &
ovarian cancer
12,13,16
NEK3 Never in mitosis
A-related kinase 3
Prolactin receptor-associated protein,
positive regulator
Enhanced survival,
motility, and invasion of
tumor cells
Ubiquitous Breast, colorectal,
carcinoid &
testicular cancer
14
PIAS3 Protein inhibitor of
activated STAT3
Prolactin receptor-associated protein,
negative regulator
Induction of malignant
transformation
Ubiquitous Breast cancer,
glioma
14
Prolactin Prolactin Growth and differentiation hormone Enhanced breast epithelial
survival and motility,
inhibition of tumor cell
apoptosis
Breast, brain
(pituitary gland),
placenta,
endometrium
Breast cancer 14,15
aOnly aromatase cytochrome P450 is investigated in this study.
Table 2. Peptide selection from the four proteins through a combined in silico
prediction and in vitro binding assay.
Protein
Size
(amino
acids)
Total number of
peptides
(9- and 10-mers)
In silico predicted
peptidesa
(9- and 10-mers)
In vitro selected
peptidesb
(9- and 10-
mers)
Aromatase 503 989 141 49
NEK3 506 995 85 36
PIAS3 628 1239 148 50
Prolactin 227 437 41 12
Total 3644 415 147
aIn silico prediction cut offs: SYFPEITHI score ≥ 19 and/or NetMHC 3.0 IC50 ≤ 1000 nM.
bIn vitro binding cut offs: A*0201: 50% of CMV control, B*0702: 70% of CMV control.
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All peptides were predicted with the 3.0 version of
NetMHC. However, at the time of publication, a new version
had been developed (NetMHCpan 4.0). Therefore, we con-
ducted a comparison of the prediction output from the cur-
rent library of the two database versions (Supplementary
Figure S2). The outputs from the two different versions of
NetMHC correlated tightly, with only few outliers represent-
ing a difference in predicted affinity between the two
databases.
Significantly more TAA-specific T cell responses were
detected ex vivo in peripheral blood from breast cancer
patients than in healthy donors
The 147 predicted breast cancer TAA peptides were synthe-
sized and used to generate individual peptide MHC (pMHC)
monomers with UV-mediated peptide exchange as previously
described.19 We then multimerized the pMHC monomers
onto a PE-labeled polysaccharide backbone, coupled to
a DNA barcode, unique to each specific pMHC (as described
in20). We included 10 epitopes from common viruses; influ-
enza virus (FLU), Epstein-Barr virus (EBV), or cytomegalo-
virus (CMV) epitopes. This yielded 157 different pMHC
multimers that were used to stain cryopreserved peripheral
blood from breast cancer patients (Patient cohort 1, n = 25)
and healthy donors (Healthy Donor cohort 1, n = 17). Based
on flow cytometry, we sorted for CD8+ T cells with the ability
to bind to pMHC multimers, the associated DNA barcodes
were amplified and the specificity of the CD8+ T cells could be
revealed by sequencing of the DNA barcodes. T cell responses
were defined as any pMHC complex enriched in the sorted
T cell fraction with p < 0.001 (FDR < 0.1%).
We observed significantlymore TAA-specific T cell responses
in patient samples than in healthy donors (Figure 1(a,b))
(Fischer’s exact test, A*0201: p < 0.0001, B*0702: p = 0.03). Of
the total 66 TAA-specific T cell responses detected, only one did
not match the HLA of the donor (sample P1.2 response to
A*0201 restricted ARO9(444) peptide). With limited patient
sample material, it was particularly advantageous to screen for
allmultimer specificities in parallel. Across 17 healthy donors, we
detected numerous T cell responses directed toward virus-
derived epitopes, validating the technical feasibility and general
immune competence of the healthy donor population. Yet,
a minor difference was observed between immune recognition
of virus-derived epitopes in patients and healthy donors.
TAA-specific T cell responses were validated by specific
expansion and cluster in immunological hotspots
To validate TAA-specific T cell responses, we specifically
expanded T cells from PBMCs, based on the responses observed
by the DNA barcoded pMHC multimer screening. Antigen-
specific T cells were stimulated using the given pMHC complex,
together with a cytokine cocktail. Following this strategy, we
observed T cell responses with frequencies >1% of CD8+ T cells
detected by multimer staining, directed toward prolactin- and
NEK3-derived peptides (Figure 2(a,b)). Additionally, for a subset
of breast cancer samples, we enriched for TAA-restrictedT cells by
magnetic bead sorting, using the entire pMHC multimer library
with all 147 peptide specificities. After magnetic bead enrichment,
samples were analyzed by DNA barcoded pMHC multimer
screening. With this strategy, a number of responses were con-
firmed and a number of additional responses were detected
(Supplementary Figure S3(a)).
In a verification cohort of breast cancer patient samples
(Patient cohort 2, n = 18) and healthy donors (Healthy Donor
cohort 2, n = 13), T cell reactivity was detected in peripheral
blood against the same TAAs. Samples in Patient cohort 2 and
Healthy Donor cohort 2 were screened for T cell reactivity
with a fluorescently labeled combinatorial-encoded pMHC
multimer library ex vivo, and after enrichment by magnetic
bead sorting. In the verification cohort, T cell responses were
distributed across the four proteins (Supplementary Figure S3
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Figure 1. Detection of T cell responses to potential breast cancer TAAs and virus derived peptides.
Screening for T cell recognition by DNA barcoded pMHC multimers in peripheral blood directly ex vivo of 25 breast cancer patients in Patient cohort 1 (a) and 17
healthy donors in Healthy Donor cohort 1 (b). Left side, T cell responses to HLA-A*0201 restricted peptides (90 breast cancer derived peptides and 7 virus derived
peptides). Right side, T cell responses to HLA-B*0702 restricted peptides (57 breast cancer derived peptides and 3 virus derived peptides). Colored circles represent
T cell responses to aromatase (green), NEK3 (orange), PIAS3 (purple), and prolactin (turquoise) derived peptides. Dark blue triangles represent T cell responses to
virus peptides from influenza virus, Epstein-Barr virus, or cytomegalovirus epitopes. Dark gray circle above dotted line represents HLA-A*0201 restricted response
detected in a patient that is not A*0201 by HLA typing. All points lying on the same vertical axis implies multiple T cell responses to the same peptide across several
donors. Data plotted on the y-axis as -Log10(p) of the relevant pMHCassociated DNA barcode. The horizontal dotted line represents the detection limit (p = 0.001/
FDR = 0.1) determining a T cell responses and all dots below are not considered as T cell responses.
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(b), Supplementary Table S2) and were preferentially observed
in breast cancer patients, as opposed to healthy donors.
All TAA-specific T cell responses detected directly ex
vivo and following pMHC-specific expansion in Patient
cohort 1 and 2 were mapped to their specific positions
along the length of the protein sequence (Figure 2(c–f)).
This analysis revealed that epitopes giving rise to T cell
responses tended to cluster, indicating potential “immuno-
logical hotspots”. Evidently, the immunological hotspots
covered certain regions of the protein sequences where
several T cell epitopes overlapped. Furthermore, multiple
T cell responses were observed toward the same epitopes
and overlapping regions across multiple breast cancer
patient samples, and with restriction to both HLA-A*0201
and –B*0702.
Each of the four investigated proteins contained targets
of TAA-specific T cells
T cell reactivity detected in peripheral blood from breast
cancer patients and healthy donors was distributed across
the four proteins, with most responses toward aromatase-
and NEK3-derived peptides (Figure 3(a)). In blood from
healthy donors, the number of T cell responses was sig-
nificantly lower than in breast cancer patients for aroma-
tase- and NEK3- derived peptides, and no T cell reactivity
was detected toward prolactin-derived peptides. With
regards to specific epitope count, it is evident that for
several T cell epitopes in aromatase and NEK3, T cell
reactivity was detected multiple times throughout a range
of screened patients (8 unique epitopes detected for each
protein, covered by 28 and 27 individual T cell responses).
For PIAS3 and prolactin, the epitopes found were more
unique for each donor, with less overlap in detection of
the same T cell response across several samples (11 and 2
unique epitopes, respectively, covered by 12 and 3 indivi-
dual T cell responses, respectively). Each protein gave rise
to a similar fraction of epitopes (16–22%) when relating
the number of T cell epitopes to the number of HLA
binding peptides, i.e. screened for T cell recognition
within each protein.
Peptides were divided into two groups, based on detection
of T cell responses (response ±), to investigate potential dif-
ferences in characteristics of immunogenic versus non-
immunogenic peptides in this context. First, evaluating the
pMHC affinity predicted by NetMHCpan 4.0 and shown as
c
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Figure 2. Validation of TAA directed T cell recognition and immunological hotspots in breast cancer antigens.
(a–b), pMHC directed expansion of T cells validated the presence of (a), A*0201 PRL9(52) specific T cells in Patient P1.8 and (b), A*0201 NEK10(329)specific T cells in
Patient P1.9 from Patient cohort 1. Frequencies of pMHC multimer specific T cells out of total CD3+ CD8+ TILs are displayed.
(c–f), Protein sequences of Aromatase (c), NEK3 (d), PIAS3 (e) and prolactin (f), with immunological hotspots illustrated. Peptide sequences, for which T cell
recognition was detected in Patient cohorts 1 & 2 are marked with red dashes (A*0201, < 3 responses), red dots (A*0201, > 3 responses), blue dashes (B*0702, < 3
responses), and blue dots (B*0702, > 3 responses).
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nM binding affinity and % eluted ligand Rank
(Supplementary Figure S4(a–b)). Second, stability was pre-
dicted by NetMHCStabpan 1.0 and shown as %Rank
(Supplementary Figure S4(c)). There were no significant dif-
ferences in mean predicted affinity or stability between pep-
tides, yielding a T cell response (+) or not (-).
T cell reactivity toward breast cancer TAAs occurs
independently of cancer subtype and disease stage
Breast cancer patients in cohort 1 were stratified into different
molecular subtypes based on pathological examination of
tumors (Supplementary Table S1). Four major subtypes of breast
cancer are commonly described based on tumor cell expression
of hormone receptors (estrogen receptor; ER, and progesterone
receptor; PR) and growth factor HER2 as follows: luminal A (ER
+ and/or PR+, HER2-), luminal B (ER+ and/or PR+, HER2+),
HER2 enriched (ER- and PR-, HER2+), and triple negative (ER-,
PR-, HER2-). Breast cancer patients with TAA-specific T cell
responses were observed for all subtypes and there seemed to be
no preferential distribution for any particular subtype in the
investigated patient cohort (Figure 3(b)). However, for certain
subtypes, i.e. HER2 enriched and triple negative, the number of
patients included is <5, and hence too few to firmly evaluate for
potential differences.
For 20 out of 25 breast cancer patients from cohort 1 it was
possible to determine disease stage based on UICC TNM
guidelines (Supplementary Table S1). Interestingly, TAA-
specific T cell responses were observed in blood from patients
at disease stage II and III, and none in blood from patients at
stage I, with significantly more responses in disease stage III
than disease stage I (Figure 3(c)). This interesting observation
from a relatively small cohort of patients at each stage (I: 4
patients, II: 12 patients, and III: 4 patients), could indicate
enhanced T cell reaction with higher tumor burden or meta-
static disease, but such findings should be validated in a larger
cohort.
Breast cancer TAA-specific T cells have functional
capacity upon stimulation
To assess the functional capacity of TAA-responsive T cells in
patients, we combined the DNA barcoded pMHC multimer
screening with measuring cytokine production by intracellular
staining, as previously described.20 A selection of PBMCs from
Patient cohort 1 were stimulated with 1) a pool of TAA peptides
specific for each patient sample, selected based on T cell
responses found by multimer screening of ex vivo or enriched
material, or 2) a mixture of HLA matching breast cancer cell
lines (BT-549, HCC1937, EFM-192A and MDA-MB-231). After
stimulation, cells were stained and analyzed simultaneously for
functional reactivity and T cell specificity by sorting T cells solely
based on their cytokine secretion profile, IFNγ and/or TNFα
secretion (ICSpos) or no cytokine secretion (ICSneg), after which
a b
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Figure 3. Distribution of detected T cell responses by protein and breast cancer subtype or stage.
Plots display distribution of T cell responses detected in breast cancer Patient cohort 1 and Healthy Donor cohort 1 ex vivo. (a), T cell response distribution across the
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sequencing of the pMHC associated DNA barcode uncovered
the antigen specificity of the sorted T cell populations.
Patient samples stimulated with peptide pools showed pre-
sence and functional capacity of T cells specific for aromatase,
NEK3, and PIAS3 peptides (Figure 4(a)). Recognition of two
peptides from aromatase with overlapping sequences (ARO9
(445) and ARO9 (444), both restricted to HLA-A*0201) were
present across most samples and cytokine-producing in some.
Relevant virus-derived peptides were included for stimulation,
with detection primarily in ICSpos T cells. Stimulation with
tumor cell lines showed T cells specific for all investigated
TAAs, but with only functional capacity for aromatase, NEK3,
and PIAS3 peptides (Figure 4(b)). Patient P1.7 had TAA-specific
T cells in the ICSneg T cell fraction, whereas patient P1.18 had
multiple TAA-specific T cells in the ICSpos T cell fraction.
Discussion
Herein, we present the detection of CD8+T cell responses toward
peptides derived from breast cancer associated antigens. The
ambition was to identify peptides from proposed breast cancer
TAAs aromatase, NEK3, PIAS3, and prolactin, and validate them
as T cell epitopes. This was accomplished by screening a cohort of
25 breast cancer patient samples and 17 healthy donor samples
for recognition of 147 selected peptides restricted to HLA-
A*0201 and -B*0702. In the primary cohort, significantly more
CD8+ T cell responses were observed in breast cancer patient
samples than healthy donor samples. This was uncovered by
a high throughput DNA-barcode label pMHC multimer
screening; a method which enabled the investigation of hundreds
of breast cancer-specific CD8+ T cells in parallel. The same
strategy was recently employed to identify autoreactive T cells
in narcolepsy.21 Our findings were confirmed in a verification
cohort (18 patients, 13 healthy donors) by fluorochrome labeled
pMHC multimers, where again CD8+ T cell responses to the
breast cancer-derived peptides were overrepresented in patient
samples versus healthy donors. Our findings across two cohorts
and two technological screening platforms show strong evidence
that the four investigated proteins contain CD8+ T cell targets.
Strikingly, epitopes were shared between patients, overlapped for
HLA*A0201 and – B*0702 and tended to cluster along the length of
the protein sequences, indicating the presence of immunological
hotspots. Importantly, upon inspection of in silico predicted proper-
ties of peptides ± CD8+ T cell recognition, it was evident that
immunogenic peptides were not significantly better binders or
more stable in theMHC complex than non-immunogenic peptides.
This emphasizes the importance of evaluating the inclusion criteria
when selecting peptides for T cell screening endeavors. As indicated
in this study, particularly when the targets are of shared origin and
the matching T cells therefore subject to stricter selection during
development in the thymus, the need for including intermediate or
even low affinity binders is of importance.
Several of the ex vivo observed CD8+ T cell responses were
verified after in vitro expansion, with expanded responses from
two patient samples validated by fluorescently-labeled pMHC
multimer staining. In addition to observing CD8+ T cell
responses ex vivo, and after specific expansion, a subset of breast
cancer patient samples were further investigated for functional
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capacity upon stimulation and ICS. Interestingly, the functional
analysis revealed breast cancer patient CD8+ T cell reactivity to
some of the TAA-derived peptides that were observed in ex vivo
screenings. A limitation of the study is the lack of patient auto-
logous tumor cells. Although we document T cell recognition of
allogeneic, commercially available cancer cell lines, the pairing of
patient T cells and autologous tumor cell lines would enable
verification of autologous recognition. The same limitation
applies to the mass spectrometry analysis, where MHC class
I expression of peptides from all four proteins was investigated
in three commercially-available breast cancer cell lines. Here one
putative HLA-A*02:01 ligand (PIAS3; SIVAPGGAL) identified
by mass spectrometry was overlapping with the T cell screening
peptide library. This peptide did not result in T cell responses.
Despite the limited overlap, the detection of four MHC class
I embedded PIAS3 peptides does document expression and
antigen-processing of PIAS3 in breast cancer.
Though breast cancer was originally considered an immuno-
logically silent malignancy, the data reported herein and recent
publications from others encourage further research of immuno-
genicity of breast cancer.22–24 In the current era of neo-epitopes
and a strong focus on personalized strategies, the breast cancer
TAAs investigated here provide a broader approachwith potential
applicability across many patients. Of note, the present study
focused on HLA-A*0201 and – B*0702, where there was already
some sequence-overlap between epitopes observed. Expanding
the analysis to additional HLA alleles would enable coverage of
a greater part of the population and possibly strengthen the
tendency of immunological hotspots. For therapeutic use, the
existence of immunological hotspots suggests a compelling
approach, where patients could be vaccinated with a long peptide
spanning a hotspot, regardless of HLA status. Such an “off-the-
shelf” antigen could possibly provide an add-on to more perso-
nalized approaches, targeting e.g., neo-epitopes. Notably, we
found TAA-specific T cell responses in all breast cancer subtypes
suggesting that a therapy based on targeting these antigens could
benefit many patients. Furthermore, TAA-specific T cell
responses seem to be enhanced at more advanced stages of dis-
ease, indicating that at an early stage of breast cancer develop-
ment, where tumor size is small and there is no spread to lymph
nodes, these tumors are less immunogenic. Also this finding
argues for enhancement of T cell reactivity by boosting the
tumor specific T cells in both frequency and functionality, e.g.
through checkpoint inhibition. Identification and understanding
of T cell epitopes can contribute to diagnostics, immunomonitor-
ing, and immunotherapy in cancer patients. This study provides
an important contribution of four novel TAAs containing multi-
ple epitopes in a poorly described landscape of breast cancer
antigens and encourages further investigation of aromatase,
NEK3, PIAS3 and prolactin in a preclinical setting, e.g. assessment
of expression and immunogenicity in mouse models.
Materials and methods
Patient and healthy donor samples
Breast cancer patient samples were kindly provided by the
Department of Oncology and the Center for Cancer Immune
Therapy, Herlev Hospital, Denmark, with approval by the
regional ethics committee for the Capital Region of Denmark.
Breast cancer patient samples came from two different cohorts,
as listed in Supplementary Table S1. All patient blood samples in
cohort 1 were drawn at the time of primary diagnosis, before any
treatment was initiated. Patients in cohort 2 were untreated, or
treated with one or more standard therapies (chemo-, radiation
and endocrine), but did not receive immunotherapy prior to
blood sampling. Healthy donor samples were collected by
approval of the local Scientific Ethics Committee, with donor
written informed consent obtained according to the Declaration
of Helsinki. Healthy donor blood samples were obtained from
the blood bank at Rigshospitalet, Copenhagen, Denmark. All
samples were obtained anonymously.
PBMC isolation from whole blood
Peripheral bloodmononuclear cells (PBMCs) from breast cancer
patients and healthy donors were obtained from whole blood
with density centrifugation on Lymphoprep (Axis-Shield PoC,
Cat#1114544) in Leucosep tubes (Greiner Bio-One, Cat#227288)
and cryopreserved at -150°C in FCS (fetal calf serum, Gibco,
Cat#10500064) + 10% DMSO (dimethyl sulfoxide, Sigma-
Aldrich, Cat#C6164).
HLA tissue typing
HLA class I tissue typing was determined by either flow
cytometry with anti-HLA-A*02 (Abcam, Cat#ab27728) and
anti-HLA-B*07 antibodies (Abcam, Cat#ab33331), PCR, or by
high-resolution next generation sequencing (IMGM,
Martinsried, Germany).
Tumor cell lines
Breast cancer cell lines were kindly provided by the Center for
Cancer ImmuneTherapy,HerlevHospital, Denmark (BT-549 and
MDA-MB-231) or purchased from ATCC (HCC1937, Cat#CRL-
2336) and DSMZ (EFM192A, Cat#ACC258) and grown in R10
(RPMI+GlutaMAXTM,Gibco,Cat#61870010+10%FCS) includ-
ing 1% penicillin-streptomycin (P/S, Sigma-Aldrich, Cat#P0781).
Expression of TAAs by tumor cell lines
Expression of proteins aromatase, NEK3, PIAS3, and prolactin
was investigated in breast cancer cell lines BT-549, EFM192A,
HCC1937, and MDA-MB-231 by intracellular staining with
anti-aromatase (Bioss, Cat#bs-1292R), anti-NEK3 (Abcam,
Cat#83221), anti-PIAS3 (Abcam, Cat#ab77231) and anti-
prolactin (Lifespan Biosciences, Cat#LS-C209024) antibodies,
with analysis by flow cytometry. Tumor cells were harvested and
washed twice in R10, once in PBS + 2% FCS. Thereafter, cells were
permeabilized and fixatedwith the Transcription Factor Buffer Set
(BD, Cat#562574) and stained for 30 min at 4°C with specific
antibodies or isotype/stain control antibodies. Followingly, cells
were washed twice in PBS + 2% FCS and stained with secondary
antibodies when relevant, washed twice in PBS + 2% FCS and
finally fixated in 1% paraformaldehyde (PFA, Santa Cruz
Biotechnology, Cat#sc-281692) until analysis.
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Endogenous peptide presentation on tumor cell lines
The endogenous MHC class I immunopeptidomes of the
breast cancer cell lines BT-549, EFM-192A and MDA-MB
-231 were analyzed by MHC immunoaffinity chromatography
(MHC-IAC) followed by liquid chromatography-mass spec-
trometry (LC-MS) as detailed in Supplementary Methods.
Briefly, each cell line was subjected to two parallel MHC-
IACs using 108 cells per analysis and employing the W6/32
antibody. Peptides were measured at a Q Exactive (Thermo
Scientific) using a top 10 data dependent acquisition strategy,
and data were processed with Proteome Discoverer version
1.4 employing Sequest HT and Percolator to achieve a false
discovery rate of 5%.
In silico HLA-A*0201 and -B*0702 binding affinity and
stability prediction of peptides
The binding affinity and stability to HLA-A*0201 and HLA-
B*0702 of 9- and 10- amino acid peptides from the four
investigated proteins were predicted by SYFPEITHI,25
NetMHC 3.0,26 NetMHCpan 4.027 and NetMHCstabpan
1.0.28 Peptides with a binding score ≥ 19 in SYFPEITHI
and/or ≤1000 nM in NetMHC 3.0 were analyzed.
Peptides
All breast cancer associated and virus-derived peptides were pur-
chased from Pepscan (Pepscan Presto BV, Lelystad, Netherlands)
and dissolved to 10 mM in DMSO. A full list of breast cancer
associated peptides used in the study can be found in
Supplementary Table S2. The following virus-derived peptides
were included in the study; HLA-A*0201 restriction: CMV pp65
(NLVPMVATV), CMV IE1 (VLEETSVML), EBV BMF1
(GLCTLVAML), EBV BRLF1 (YVLDHLIVV), EBV LMP2
(CLGGLLTMV), EBV LMP2 (FLYALALLL), FLU MP
(GILGFVFTL), HIV pol (ILKEPVHGV), HLA-B*0702 restric-
tion: CMV pp65 (RPHERNGFTV), CMV pp65
(TPRVTGGGAM), EBV EBNA (RPPIFIRLL).
In vitro affinity testing and selection of peptides
The experimental binding of in silico predicted peptides was
assessed by MHC ELISA, as previously described by
Rodenko et al.19 Briefly, biotinylated peptide-HLA (pHLA)-
A*0201/B*0702 complexes were generated by UV-mediated
peptide exchange and incubated on streptavidin (Invitrogen,
Cat#S888)-coated Maxisorp plates (NUNC, Cat#44-2404-21)
for 1 h at 37°C. The pHLA complexes were then incubated
with horseradish peroxidase-conjugated β2 microglobulin
(β2m) antibody (Acris GmbH, Cat# 604HRP) for an addi-
tional 1 h at 37°C, binding only to correctly folded peptide-
MHC (pMHC) molecules. Plates were washed and
a colorimetric reaction was initiated by the addition of tetra-
methylbenzidine peroxidase substrate (KPL, Cat#506606).
Finally, the optical density (OD) of each well was measured
at 405 nm by an ELISA reader (Epoch microplate spectro-
photometer, Bio-Tek) and values were normalized to the OD
of a CMV-derived virus peptide with a known high binding
affinity by the formula,
Index value ¼ ODpeptide  ODPBS
ODCMVcontrol peptide
HLA-binding peptides were selected based on their ability to
rescue the A*0201/B*0702 molecule from degradation after
UV-mediated cleavage of the conditional ligand and com-
pared to that of a CMV virus-derived control with known
high binding affinity. The threshold for selection was set at
50% (A*0201) and 70% (B*0702) of the binding affinity of the
respective virus-derived peptides.
MHC monomer production and generation of specific
pMHC multimers
The production of MHC monomers was performed as pre-
viously described by Hadrup et al.29 In brief, HLA-A*0201
and -B*0702 heavy chains and human β2m light chain were
expressed in bacterial BL21 (DE3) pLysS strain (Novagen,
Cat# 69451) and purified as inclusion bodies. After solubili-
zation, A*0201/B*0702 inclusion bodies were refolded with
β2m light chain and a UV-sensitive ligand,
30,31 and the
folded monomers were biotinylated with BirA biotin-
protein ligase standard reaction kit (Avidity, 318 LLC-
Aurora, Colorado) and purified using a size-exclusion col-
umn (Waters, BioSuite125, 13µm SEC 21.5 × 300 mm) and
HPLC (Waters 2489). Specific pMHC monomers were gen-
erated by UV-induced peptide exchange30 and multimerized
with fluorochrome-conjugated streptavidin or coupled to
dextramer according to specific protocols.
Enrichment of pMHC-specific T cells by magnetic bead
sorting
Cryopreserved PBMCs were thawed and washed in R10 media
containing DNase (40 U/ml, Stem Cell Technologies,
Cat#07900) before incubation with PE (phycoerythrin)-
coupled pMHC multimers (0.1 mg of each specificity) for
1 h at 4°C. Hereafter, cells were washed twice in R10 and
incubated 15 min at 4°C with anti-PE microbeads (Miltenyi
Biotec, Cat#130-048-801). Cells were washed twice after incu-
bation, resuspended in 0.5 mL RPMI with DNase and applied
to magnetic separation columns (MS; Miltenyi Biotec;
Cat#130-042-201) placed in a magnetic field of a magnetic-
activated cell sorting (MACS) separator through a 30 µm pre-
separation filter. After washing, cells were flushed out in 2mL
X-vivo (Lonza, Cat#Be04-418Q), 5% human serum, 100 U/mL
IL-2 (Proleukin; Novartis, Cat#200-02), 15 ng/mL IL-15
(Peprotech, Cat#200-15), centrifuged and resuspended in
200 µL of the same media containing 5 × 104 feeder cells,
prepared and irradiated from the negative fraction during
separation and 5 × 103 anti-CD3/CD28-coated Dynabeads
(Invitrogen, Cat#111.31.D). Enriched cells were cultured in
96-well plates for 2–3 weeks, with bi-weekly change of med-
ium and analyzed by pMHC multimer-specific T cell detec-
tion methods.
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pMHC-specific expansion of T cells
Cryopreserved PBMCs were thawed and washed in R10
media, resuspended and cultured in X-vivo + 5% human
serum. Cells were stimulated twice a week with the given
pMHC complex, IL-2 and IL-21, all co-complexed on
a dextran molecule for expansion of specific T cell popula-
tions and analyzed after two weeks by combinatorial fluores-
cently-encoded pMHC multimers.
Detection of pMHC-specific T cells by combinatorial
fluorescently-encoded MHC multimers
The combinatorial encoding method and gating strategy is
described in detail by Andersen et al.32 Briefly, a UV exchange
reaction was carried out for each selected HLA-A*0201/B*0702
peptide ligand, followed by multimerization on two different
streptavidin-conjugated fluorochromes. Thus, each of the peptide
specificities was assigned a unique two-color combination. Five
different streptavidin-conjugated fluorochromes were used for
detection of specific T cells in Patient cohort 1: PE (phycoerythrin,
Biolegend, Cat#405203), APC (allophycocyanin, Biolegend,
Cat#405207), PE-Cy7 (phycoerythrin-cyanin 7, Biolegend,
Cat#405206), PE-CF594 (BD, Cat#562284), and BV421 (brilliant
violet, Biolegend, Cat#405226). Nine streptavidin-conjugated
fluorochromes were used for detection of specific T cells in
Patient cohort 2 and Healthy Donor cohort 2: PE, APC, PE-
Cy7, BV421, Q-dot 585 (quantum dot, Invitrogen: Q10111MP),
Q-dot 605 (Invitrogen, Cat#Q10101MP), Q-dot 625 (Invitrogen,
Cat#A10196), Q-dot655 (Invitrogen: Q10121MP) and Q-dot705
(Invitrogen, Cat#Q10161MP). Breast cancer and healthy donor
PBMCs were stained with a panel of up to 36 combinatorially
encoded pMHC-multimers at a time, followed by staining with an
antibody mix consisting of either CD8-BV480 (BD, Cat#566121
(clone RPA-T8)) in Patient cohort 1 or CD8-PerCP (Invitrogen,
Cat#MHCD0831) in Patient cohort 2 and Healthy Donor cohort
2, dump channel antibodies CD4-FITC (CD4- fluorescein iso-
thiocyanate, BD, Cat#345768), CD14-FITC (BD, Cat#345784)
CD19-FITC (BD, Cat#345776), CD16-FITC (BD, Cat#335035)
and CD40-FITC (Bio-rad, Cat#MCA1590F), and the dead cell
marker LIVE/DEAD Fixable Near-IR (Invitrogen, Cat#L10119).
Multimer positive T cell responses were gated as single, live,
CD8+, FITC− (dump channel), multimer color 1+, multimer
color 2+, and negative for the remaining multimer colors, and
defined by a minimum of 10 dual color positive events.
Detection of pMHC-specific T cells by barcoding
DNA-barcoded pMHCmultimers were used to screen for T cell
recognition against 157 pMHC specificities in a single sample.
Themethod is described in detail in Bentzen et al.20 Briefly, a UV
exchange reactionwas carried out for each selectedHLA-A*0201
/B*0702 peptide ligand, as described above. Each generated
pMHC complex was coupled to DNA barcode- and PE-labeled
dextran backbones, so that each specific peptide was encoded by
a uniqueDNA barcode. Breast cancer and healthy donor PBMCs
were stained with a pool of all barcodedMHC-multimers and an
antibody mix of CD8-BV480, dump channel antibodies CD4-
FITC, CD14-FITC, CD19-FITC, CD16-FITC, and CD40-FITC,
and the dead cell marker LIVE/DEAD Fixable Near-IR.
Multimer-specific T cells were then sorted as single, live, CD8+,
FITC− (dump channel), PE+ fraction of cells, pelleted by centri-
fugation and cryopreserved at -80ºC. DNA barcodes were ampli-
fied from the cell pellet and from a stored aliquot of the pMHC
multimer reagent pool (used as baseline for comparison) by
PCR, purified with a QIAquick PCR Purification kit (Qiagen,
Cat#28104) and sequenced (Sequetech) using an Ion Torrent
PGM 316 or 318 chip (Life Technologies). Sequencing data were
processed by the software package Barracoda, available online at
www.cbs.dtu.dk/services/barracoda. This tool identifies bar-
codes used in a given experiment, assigns sample ID and
pMHC specificity to each barcode, and counts the total number
of reads and clonally-reduced reads for each pMHC-associated
DNA barcode. Log2 fold changes in read counts mapped to
a given sample relative to the mean read counts mapped to
triplicate baseline samples are estimated with normalization
factors determined by the trimmed mean of M-values method.
False-discovery rates (FDRs) were estimated using the
Benjamini–Hochberg method. A p-value is calculated based on
the Log2 fold change distribution, determining the strength of
the signal compared to the input. Also, p < 0.001, corresponding
to FDR < 0.1%, is established as the significance level determin-
ing a T cell response.
Functional assessment of pMHC-specific T cells by
barcoding and intracellular flow cytometry
The functionality of pMHC-specific T cells was tested by com-
bining intracellular cytokine staining (ICS) with a DNA bar-
code-based pMHCmultimer staining, as previously described in
Bentzen et al.20 Briefly, patient-derived PBMCs were stimulated
with either pre-stimulated IFNγ (PreproTech, Cat#300-02)
breast cancer cell lines at a 10:1 ratio (PBMCs:cell lines), a pool
of peptides with known reactivity in the specific patient or
a leucocyte activation cocktail (LAC, BD, Cat#550583) positive
control for 4 h at 37°C. After stimulation, cells were stained with
barcoded MHC multimers, followed by staining with extracel-
lular surface antibodies: CD3-FITC (BD, Cat#345763), CD8-
BV480, and dead cell marker LIVE/DEAD Fixable Near-IR.
Hereafter cells were permeabilized with the Intracellular Fix
and Perm kit (eBioscience, Cat#88-8824-00), stained with intra-
cellular antibodies TNFα-PE-Cy7 (BioLegend, Cat#502930) and
IFNγ-APC (BD, Cat#341117), and fixated in 1% PFA until
analysis.
Flow cytometry
All flow cytometry experiments were carried out on LSRII,
Fortessa, and AriaFusion instruments (BD Biosciences). Data
were analyzed in FACSDiva Software version 8.0.2 (BD
Biosciences) and FlowJo version 10.4.2 (TreeStar, Inc.)
Statistical analyses
GraphPad Prism 7 for Mac OS X was used for graphing, statis-
tical analyses and tools. This study included the D’agostino-
Pearson omnibus normality test, unpaired parametric T-test
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(following log-transformation to reach Gaussian distribution as
needed), nonparametric Mann-Whitney test, Fischer’s exact test,
and Pearson’s correlation coefficient.
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